Opening soon
Trial summary
A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.
Trial details
Short title
BAY 3713372
Diagnosis
Lung cancer
Advanced solid tumours
Pancreatic cancer
Type of treatment
Medical Oncology
Phase
I / II
Locations
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.